By Vincent Couey, RxGrab founder. Reviewed by Vincent Wesley Couey. Updated .
Zepbound (tirzepatide) and Wegovy (semaglutide) are the two FDA-approved GLP-1 medications for chronic weight management, and they are the two most-searched drugs in the category. For years the practical choice was muddied by wildly different cash prices and patchy insurance. Two things changed that in 2026: a direct clinical comparison finally settled the effectiveness question, and manufacturer self-pay programs collapsed the price gap. This guide covers both, with the real numbers. For the semaglutide-specific savings paths, see our full Ozempic and semaglutide cost breakdown.
Until 2025 there was no direct trial pitting the two drugs against each other, so comparisons relied on separate studies. SURMOUNT-5 changed that. Published in the New England Journal of Medicine, it randomized 751 adults with obesity and without type 2 diabetes to the maximum tolerated dose of either Zepbound or Wegovy for 72 weeks. The result was clear:
| Outcome (SURMOUNT-5, 72 weeks) | Zepbound (tirzepatide) | Wegovy (semaglutide) |
|---|---|---|
| Average body-weight reduction | 20.2% | 13.7% |
| Approximate pounds lost | ~50 lb | ~33 lb |
| Waist circumference reduction | 18.4 cm | 13.0 cm |
| Receptors activated | GIP + GLP-1 (dual) | GLP-1 only |
Head-to-head weight loss, SURMOUNT-5 (72 weeks)
The practical read: Zepbound is the more effective drug for weight loss on average, by a meaningful margin (roughly a third more weight lost). That does not mean Wegovy is ineffective, 13.7% is a strong result that clears the bar for clinically significant weight loss. But if maximum weight loss is the goal and you tolerate the drug, the trial favors Zepbound.
On the only head-to-head trial, Zepbound lost about a third more weight than Wegovy, 20.2% versus 13.7%.SURMOUNT-5, NEJM 2025
This is the part most older comparison pages get wrong. They still quote Wegovy at roughly $1,350 a month and Zepbound around $1,060, which made Wegovy look expensive and Zepbound look like the value pick, or vice versa depending on the year. In 2026 both manufacturers sell direct to self-pay patients, and the numbers are now close together and far below old retail.
| Path | Zepbound (tirzepatide) | Wegovy (semaglutide) |
|---|---|---|
| Direct self-pay vials (2026) | $299 (2.5mg) / $399 (5mg) / $449 (7.5-15mg) | ~$350/mo direct |
| Via TrumpRx platform | ~$350/mo | ~$350/mo (from ~$1,350 retail) |
| Old retail cash price | ~$1,060/mo | ~$1,350/mo |
| With commercial coverage + savings card | as low as $25/mo | as low as $0-$25/mo |
Zepbound single-dose vials through LillyDirect were reduced in 2026 to $299 a month at 2.5 mg, $399 at 5 mg, and $449 for every dose from 7.5 mg through 15 mg (with a 45-day refill window required to hold the $449 ceiling on higher doses). Wegovy is now about $350 a month direct, a dramatic drop from its roughly $1,350 retail price. In other words, on self-pay the two land within about $100 of each other, and the higher-dose Zepbound vial at $449 is the only meaningful spread. The "Wegovy is the budget option" era is over.
Zepbound
tirzepatide, dual GIP/GLP-1
20.2% weight loss
Wegovy
semaglutide, GLP-1 only
13.7% weight loss
Effectiveness and price no longer split cleanly, so the decision comes down to your specific circumstances:
Both drugs are once-weekly self-injections, and both are titrated up slowly over several weeks so your body adjusts. The side-effect profiles are broadly similar because both act on the GLP-1 pathway: nausea, diarrhea, constipation, and vomiting are the most common, usually worst during dose increases and easing over time. Both carry a boxed warning about a risk of thyroid C-cell tumors seen in animal studies and should not be used by people with a personal or family history of medullary thyroid carcinoma or MEN 2. Zepbound's dual mechanism does not appear to make side effects meaningfully worse than Wegovy's despite the greater weight loss. As always, this is general information, your prescriber should guide dosing, titration, and any switch between the two.
Zepbound (tirzepatide) produced more weight loss than Wegovy (semaglutide) in SURMOUNT-5, the first head-to-head trial, published in the New England Journal of Medicine in 2025. Over 72 weeks in 751 adults with obesity and no diabetes, Zepbound led to a 20.2% average body-weight reduction (about 50 pounds) versus 13.7% for Wegovy (about 33 pounds), and reduced waist circumference more (18.4 cm vs 13.0 cm). Zepbound activates two receptors, GIP and GLP-1; Wegovy activates only GLP-1.
They are now close. Both are sold direct to self-pay patients at similar prices. Zepbound single-dose vials through LillyDirect run $299/month at 2.5 mg, $399 at 5 mg, and $449 for 7.5 mg through 15 mg, or about $350/month through TrumpRx. Wegovy is now about $350/month direct, down from roughly $1,350 at retail. The old assumption that Wegovy is dramatically cheaper no longer holds; on self-pay the two are within about $100 of each other.
Both are once-weekly injections approved for chronic weight management. Wegovy is semaglutide (the same molecule as Ozempic) and activates the GLP-1 receptor. Zepbound is tirzepatide (the same molecule as Mounjaro) and activates two receptors, GIP and GLP-1. In the SURMOUNT-5 head-to-head trial Zepbound produced greater weight loss. Both require a prescription, are titrated up over several weeks, and are now available as self-pay vials in addition to prefilled pens.
Coverage for weight loss is inconsistent for both. Many commercial plans exclude GLP-1 drugs when prescribed solely for weight management, and Medicare does not cover either for weight loss. Because coverage is unreliable, the 2026 self-pay direct programs (LillyDirect for Zepbound, NovoCare or TrumpRx for Wegovy) have become the practical path for many patients. Check your plan's formulary and ask about prior authorization.
Many patients do, usually to pursue greater weight loss or because of coverage changes, but switching should be done with a prescriber. The two are not dosed one-to-one: your doctor will start you on a low Zepbound dose (2.5 mg) and titrate up regardless of your prior Wegovy dose, to manage side effects. Do not switch on your own or overlap the two.
We track direct-pay pricing, savings programs, and coverage changes for Zepbound, Wegovy, and the rest.